Téléversements by John

Novexatin Expert Clinical Opinion

Taro Why the Valuation Discount(1)

Voice of Shareholders_Survey

Shareholder Proposals - Annual Shareholders Meeting

Unconfirmed 645671

Anacor Investor Presentation June 2013 [Compatibility Mode]

herbalife long thesis dan leob

TARO VIC thesis

Perrigo Guidance

12 Civ 8195 Complaint

Dear Members of the TARO Boardv2-0927-Letter

Fusilev (Levoleucovorin) Humana Coverage Policy

13282145-marine

Doc1

Doc1

001 Investor Presentation June2012

13272520

Knight

13272520-6

13272520-6

13272520-3

13272520-3

13272520-4

Amrn Response to Final Rejection

TarominorityshareholderspetitiontoSpecialCommitteeandBoard-05202012

AckmanJCP

amended claims-marine

Patent case

Marine patent applicant arguments

Lavin declaration

Disclosure Comparison

Taro Growth

TARO Valuation 2

bac

Disclosure Comparison

TARO Valuation

TaroPharmaceuticalIndustriesLtd_6K_20120405

TaroPharmaceuticalIndustriesLtd_20F_20120405

12815569

TARO EBIDTA and Sales Growth

Linked to Win September 14 2011

12769885(2)

12769885(1)

12769885

Taro pharma 3 years sales and ebidta growth

13272520

12052598

07902500_fj_11_1994

07902500-amended_claims_08_1994